Frank Karbe - 07 Jul 2021 Form 4 Insider Report for Myovant Sciences Ltd.

Reporting relationship: Principal Fin'l & Accounting
Issuer ticker: N/A
Reported as of: 07 Jul 2021
Net transaction value: -$70,296
SEC form: 4
Accepted by SEC: 09 Jul 2021, 16:27:07 UTC
Next SEC filing: 26 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Matthew Lang, Attorney-in-fact

Key filing fact

Frank Karbe filed Form 4 for Myovant Sciences Ltd. on 09 Jul 2021.

Key facts

This page summarizes Frank Karbe's Form 4 filing for Myovant Sciences Ltd..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Jul 2021, 16:27.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$70,296.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MYOV transaction

Common Shares

Sale

Transaction value: $70,296
Shares: -3,232
Change %: -1.5%
Price: $21.75
Shares after: 212,296
Date: 07 Jul 2021
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

Footnote F2

The shares were sold at prices ranging from $21.75 to $21.83. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.